


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
PHR
Phreesia Inc.
$15.78
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
PHR Price Performance
$19.05 (-17.17%)
$23.5 (-32.85%)
$26.55 (-40.56%)
$25.19 (-37.36%)
PHR has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

PHR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a weak earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
PHR Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
PHR Street Sentiment is unimpressive and have negative views on the near-term outlook
Average key support and resistance price levels
Login to displayWhat is PHR current stock price?
What are PHR stock strengths?
What is PHR Risk Level?
What is PHR market cap and volume?
What is PHR current Stock IQ?
Should I buy PHR stock right now?
Is PHR a Strong Buy right now?
What does a 'Strong Buy' rating mean for PHR?
What does a 'Strong Sell' rating mean for PHR?
What factors influence PHR's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
PHR
Phreesia Inc.
Current Price
$15.78
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

PHR Price Performance
$19.05 (-17.17%)
$23.5 (-32.85%)
$26.55 (-40.56%)
$25.19 (-37.36%)
PHR Analysts Opinion
PHR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a weak earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
PHR Analysts opinion is negative but has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
PHR Street Sentiment is unimpressive and have negative views on the near-term outlook
PHR has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
PHR Stock IQ
PHR Latest Analysis
Phreesia (PHR) Loses 32.2% in 4 Weeks Heres Why a Trend Reversal May be Around the Corner. Phreesia (PHR) is technically in oversold territory now so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Today
Barclays Initiates Coverage of Phreesia (PHR) with Overweight Recommendation. Fintel reports that on December 9 2025 Barclays initiated coverage of Phreesia (NYSE:PHR) with a Overweight recommendation. Analyst Price Forecast Suggests 71.35% Upside
Today
JP Morgan Maintains Phreesia (PHR) Overweight Recommendation. Fintel reports that on December 9 2025 JP Morgan maintained coverage of Phreesia (NYSE:PHR) with a Overweight recommendation. Analyst Price Forecast Suggests 71.35% Upside
Today
Canaccord Genuity Maintains Phreesia (PHR) Buy Recommendation. Fintel reports that on December 9 2025 Canaccord Genuity maintained coverage of Phreesia (NYSE:PHR) with a Buy recommendation. Analyst Price Forecast Suggests 71.35% Upside
Today
Needham Reiterates Phreesia (PHR) Buy Recommendation. Fintel reports that on December 9 2025 Needham reiterated coverage of Phreesia (NYSE:PHR) with a Buy recommendation. Analyst Price Forecast Suggests 71.35% Upside
Today
Citigroup Maintains Phreesia (PHR) Buy Recommendation. Fintel reports that on December 9 2025 Citigroup maintained coverage of Phreesia (NYSE:PHR) with a Buy recommendation. Analyst Price Forecast Suggests 71.35% Upside
Today
Why Phreesia Stock Plummeted by 23% Today. Key PointsInvestors enthusiastically traded out of the stock despite its good performance across all three business lines.
Tue Dec 9, 2025
Phreesia Inc. (NYSE:PHR) Q3 2026 Earnings Call Transcript. Phreesia Inc. (NYSE:PHR) Q3 2026 Earnings Call Transcript December 8 2025 Phreesia Inc. misses on earnings expectations. Reported EPS is $0.1 EPS expectations were $0.36. Operator: Ladies and gentlemen thank you for standing by. My name is Abby and I will be your conference operator today. At this time I would like to welcome everyone [….]
Tue Dec 9, 2025
Phreesia Swings To Q3 Profit Revises FY26 Outlook Issues FY27 Guidance . (RTTNews) - Phreesia Inc. (PHR) an integrated SaaS-based software and payment platform provider for the healthcare industry on Tuesday reported a profit for the third quarter of fiscal 2026 reversing a loss from the prior year quarter.
Tue Dec 9, 2025
Phreesia outlines $545M–$559M fiscal 2027 revenue target as AccessOne acquisition expands provider financing and HCP marketing reach.
Mon Dec 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.